Collegium Pharmaceutical, Inc.
COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to requirā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$27.54
Price-4.18%
-$1.20
1Y
Price
Market Cap
$893.226m
Small
Price/Earnings 3y Avg5y Avg
3.5x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+46.8%
EBITDA Margin+7.5%
Net Profit Margin+29.4%
Free Cash Flow Margin+46.8%
EBITDA Margin+7.5%
Net Profit Margin+29.4%
Free Cash Flow MarginRevenue
$796.330m
+2.0%
1y CAGR+12.4%
3y CAGR+14.8%
5y CAGREarnings
$74.949m
+19.2%
1y CAGR+17.9%
3y CAGR+86.6%
5y CAGREPS
$2.04
+17.9%
1y CAGR+18.4%
3y CAGR+82.4%
5y CAGRBook Value
$312.422m
$1.652b
Assets$1.340b
Liabilities$808.056m
DebtDebt to Assets
48.9%
1.3x
Debt to EBITDAFree Cash Flow
$329.826m
+0.7%
1y CAGR+12.0%
3y CAGR+39.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company